

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

#4

COSME ET AL

Atty. Ref.: 620-347

Serial No. 10/516,338

Group: Unassigned

Filed: November 30, 2004

Examiner: Unassigned

For: METHODS OF PURIFICATION OF CYTOCHROME P450
PROTEINS AND OF THEIR CRYSTALLIZING

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 15, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] \$180.00
3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By:



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

CITATION

620-347

10/516,338

APPLICANT

COSME ET AL

(Use several sheets if necessary)

FILING DATE

GROUP

November 30, 2004

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,786,191	07/1998	Goldstein et al.			
	5,834,250	11/1998	Wells et al.			
	5,886,157	03/1999	Guengerich et al.			
	5,912,120	06/1999	Goldstein et al.			
	6,080,568	06/2000	Day et al.			
	6,136,553	10/2000	Christianson et al.			
	6,162,613	12/2000	Su et al.			
	2003/0170842	09/2003	Williams et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES NO
WO 98/02554	01/1998	WIPO			
WO 01/11035	02/2001	WIPO			
WO 01/14565	03/2001	WIPO			
WO 03/035693 A	05/2003	WIPO			
WO 03/040994 A	05/2003	WIPO			
WO 03/102192	12/2003	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	von Wachenfeldt, C.; Richardson, T.; Cosme, J. and Johnson, E.; Microsomal P450 2C3 Is Expressed as a Soluble Dimer in <i>E. coli</i> Following Modifications of Its N-terminus, <i>Archives of Biochemistry and Biophysics</i> , 1997, Vol. 339, No. 1, pp. 107-114.
	Cosme, J. and Johnson, E.; Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble Monomeric Enzyme, <i>Journal of Biological Chemistry</i> , 2000, Vol. 275, No. 4, pp. 2545-2553.
	Williams, P.; Cosme, J.; Sridhar, V.; Johnson, E. and McRee, D.; Mammalian Microsomal Cytochrome P450 Monooxygenase: Structural Adaptations for Membrane Binding and Functional Diversity, <i>Molecular Cell</i> , 2000, Vol. 5, pp. 121-131.
	Williams, P.; Cosme, J.; Sridhar, V.; Johnson, E. and McRee, D.; Microsomal cytochrome P450 2C5: comparison of microbial P450s and unique features, <i>Journal of Inorganic Biochemistry</i> , 2000, Vol. 81, pp 183-190.
	T. H. Richardson, F. Jung, K. J. Griffin, M. Wester, J. L. Raucy, B. Kemper, L. M. Bornheim, C. Hassett, C. J. Omiecinski and E. F. Johnson; A Universal Approach to the Expression of Human and Rabbit Cytochrome P450s of the 2C Subfamily in <i>Escherichia coli</i> ; <i>Archives of Biochemistry and Biophysics</i> , 1995, Volume 323, 87-96.
	JP10033166A2; Mass Expression System Of Modified Substance Of Cytochrome P450 2C19 In <i>Escherichia Coli</i> ; Inventor: Baba Takahiko; Kiritia Shiro; Aoyama Junko; Assignee: Shionogi & Co Ltd; Filed: July 23, 1996. Filed together with English abstract.
	Barnes HJ, Arlotto MP, Waterman MR; Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in <i>Escherichia coli</i> ; <i>Proc. Natl. Acad. Sci. USA</i> ; 1991, 88, 5597-5601.
	Kempf AC, Zanger UM, Meyer UA; Truncated human P450 2D6: expression in <i>Escherichia coli</i> , Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation; <i>Arch. Biochem. Biophys.</i> , 1995, 321, 277-288.
	Gillam EM, Guo Z, Martin MV, Jenkins CM, Guengerich FP; Expression of cytochrome P450 2D6 in <i>Escherichia coli</i> , purification, and spectral and catalytic characterization; <i>Arch. Biochem. Biophys.</i> , 1995, 319, 540-550.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

CITATION

620-347

10/516,338

APPLICANT

COSME ET AL

(Use several sheets if necessary)

FILING DATE

GROUP

November 30, 2004

Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
	Pernecke SJ, Larson JR, Philpot RM, Coon MJ; Expression of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli; influence of NH2-terminal region on localization in cytosol and membranes; <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2651-2655.
	JR Larson, MJ Coon, and TD Porter; Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli; <i>J. Biol. Chem.</i> , 1991, 266, 7321-7324.
	Sagara Y., Barnes H. J. and Waterman M. R.; Expression in <i>Escherichia coli</i> of Functional Cytochrome P450 _{c17} Lacking Its Hydrophobic Amino-Terminal Signal Anchor, <i>Arch. Biochem. Biophys.</i> , 1993, 304, 272-278.
	Gillam EM, Baba T, Kim BR, Ohmori S, Guengerich FP; Expression of modified human cytochrome P450 3A4 in <i>Escherichia coli</i> and purification and reconstitution of the enzyme; <i>Arch Biochem Biophys.</i> , 1993; 305(1); 123-31.
	Emily E. Scott, Margit Spatzenegger and James R. Halpert ; A Truncation of 2B Subfamily Cytochromes P450 Yields Increased Expression Levels, Increased Solubility, and Decreased Aggregation While Retaining Function, <i>Arch. Biochem. Biophys.</i> , 2001, Volume 395, Issue 1, 57-68.
	Meehan,R.R., Gosden,J.R., Rout,D., Hastie,N.D., Friedberg,T., Adesnik,M., Buckland,R., van Heyningen,V., Fletcher,J.M., Spurr,N.K., Sweeney,J. and Wolf,C.R.; Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10; <i>Am. J. Hum. Genet.</i> ; 1988, 42 (1), 26-37.
	Kimura,S., Pastewka,J., Gelboin,H.V. and Gonzalez,F.J.; cDNA and amino acid sequences of two members of the human P450IIC gene subfamily; <i>Nucleic Acids Res.</i> ; 1987, 15 (23), 10053-10054.
	Romkes,M., Faletto,M.B., Blaisdell,J.A., Raucy,J.L. and Goldstein,J.A.; Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily; <i>Biochemistry</i> ; 1991, 30 (13), 3247-3255.
	Gonzalez,F.J., Vilbois,F., Hardwick,J.P., McBride,O.W., Nebert,D.W., Gelboin,H.V. and Meyer,U.A.; Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22; <i>Genomics</i> , 1988, vol 2 (2), 174-179.
	Hasemann, C. A. et al., Crystal Structure and Refinement of Cytochrome P450terp at 2.3 Å resolution <i>J. Mol. Biol.</i> 236(4) 1169-1185 (1994)
	Lewis, David F. V. et al., Homology Modelling of Human Cytochromes P450 involved in Xenobiotic Metabolism and Rationalization of Substrate Selectivity <i>Experimental and Toxicologic Pathology</i> 51(4-5) 369-374 (1999)
	Ibeano GC, Ghanayem BI, Linko P, Li L, Pederson LG, Goldstein JA.; Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity; <i>J. Biol. Chem.</i> , 1996, Vol. 271, 12496-12501
	David R. Nelson et al., P450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, <i>Pharmacogenetics</i> 6 1-42 (1996).
	Nienaber et al., Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite, <i>J. Biol. Chem.</i> 275(10) 7239-7248 (2000)
	Dale et al., Crystal Engineering: deletion mutagenesis of the 24 kDa fragment of the DNA gyrase B subunit from <i>Staphylococcus aureus</i> , <i>Acta Crystallographica D55</i> , 1626-1629 (1999)
	Wolfram Schiweck and Arne Skerra, The Rational Construction of an Antibody against Cystatin: Lessons from the crystal structure of an artificial Fab fragment, <i>J. Mol. Biol.</i> 268 934-951 (1997)
	Stephen R. Price and Kiyoshi Nagai, Protein Engineering as a Tool for Crystallography, <i>Current Opinion in Biotechnology</i> 6 425-430 (1995)
	Lawson et al., Solving the Structure of Human H Ferritin by Genetically Engineering Intermolecular Crystal Contacts, <i>Nature</i> 349 541-544 (1991)
	Park et al., Crystallization and preliminary X-ray diffraction analysis of a cytochrome P450 (CYP119) from <i>Sulfolobus Solfataricus</i> , <i>Acta Crystallographica Section D Biological Crystallography</i> , Vol. 56, No. 9, September 2000 (2000-09), pages 1173 - 1175

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	620-347	10/516,338
	APPLICANT	
(Use several sheets if necessary)	COSME ET AL	
	FILING DATE	GROUP
	November 30, 2004	Unassigned

*EXAMINER INITIAL	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
	Ridderström et al., Arginines 97 and 98 in CYP2C9 are important determinants of the catalytic function, Biochemical and Biophysical Research Communications 270, 983-987 (2000)
	Payne et al., Homology modelling and substrate binding study of human CYP2C9 enzyme, Proteins, vol. 37, no. 2, 1 November 1999, pages 176 - 190
	Ekins et al., Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites, Drug Metabolism and Disposition, Vol. 29, No. 7, July 2001, pages 936-944
	Stubbins et al., Genetic analysis of the human cytochrome P450 CYP2C9 locus, Pharmacogenetics (1996) 6, 429 - 439
	Afzelius Lovisa et al., Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis, Molecular Pharmacology, April 2001; Vol. 59, no. 4: 909 - 919
	Lewis, D. F. V., Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes, Archives of Biochemistry and Biophysics; Vol. 409, no. 1 (2003), 32 - 44
	Williams P A et al., Crystal structure of human cytochrome P450 2C9 with bound warfarin, Nature, 2003, Jul. 24; 424(6947): 464 - 468
	De Groot, Marcel J et al., Development of a combined protein and pharmacophore model for cytochrome P450 2C9, J. Med. Chem., 2002, Vol. 45, no. 10, 1983 - 1993
	Blundell, T. L. et al., High throughput crystallography for lead discovery in drug design, Nature Reviews. Drug Discovery, Nature Publishing Group, Basingstoke, GB; Vol. 1, no. 1, Jan. 2002, 45 - 54
	Pamela A. Williams, Jose Cosme, Dijana Matak Vinkovic, Alison Ward, Hayley C. Angove, Philip J. Day, Clemens Vonrhein, Ian J. Tickle, Harren Jhoti; Crystal structures of human cytochrome P450 3A4 bound to Metyrapone and Progesterone, Science, 30 July 2004; 305: 683 - 686
	Jason K. Yano, Michael R. Wester, Guillaume A. Schoch, Keith J. Griffin, C. David Stout and Eric F. Johnson; The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-Ray Crystallography to 2.05-Å Resolution, J. Biol. Chem., Sep 2004; 279: 38091 - 38094
	Gonzalez FJ, Schmid BJ, Umeno M, McBride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR; Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase, DNA; 1988; 7(2); 79 - 86
	Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP, Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase, Proc. Natl. Acad. Sci. U.S.A.; 1986; 83(21); 8064 - 8068
	Wester et al, The Journal of Biological Chemistry, August 2004, Vol. 279, pp 35630-35637
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-347	10/516,338
		APPLICANT	
		COSME ET AL	
(Use several sheets if necessary)		FILING DATE	GROUP
		November 30, 2004	Unassigned

*EXAMINER INITIAL	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
	Hutzler, et al., "Activation of cytochrome 2C9-mediated metabolism: mechanistic evidence in support of kinetic observation"; <i>Archives of Biochemistry and Biophysics</i> ; 2003, 410, 16-24.
	Hutzler, et al., "Activation Of CYP2C9-Mediated Metabolism By A Series Of Dapsone Analogs: Kinetics And Structural Requirements"; <i>Drug Metabolism and Disposition</i> , 2002, Vol 30, pp 1194-1200.
	Hutzler, et al., "Dapsone Activation Of CYP2C9-Mediated Metabolism: Evidence For Activation Of Multiple Substrates And A Two-Site Model"; <i>Drug Metabolism and Disposition</i> , 2001, Vol 29, 1029-1034.
	Korzekwa, et al., "Evaluation Of Atypical Cytochrome P450 Kinetics With Two-Substrate Models: Evidence That Multiple Substrate Can Bind Simultaneously Bind To Cytochrome P450 Active Sites"; <i>Biochemistry</i> ; 1998, Vol 37, 4137-4147.
	Melet, et al., "Substrate selectivity of human cytochrome P450 2C9: importance of residues 476,365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid", <i>Archives of Biochemistry and Biophysics</i> , Volume 409, Issue 1, 1 January 2003, Pages 80-91.
	He, et al., "Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9"; <i>Arch Biochem Biophys</i> . 1999 Dec 1;372(1):16-28.
	Kaminsky, et al., "Human P450 metabolism of warfarin"; <i>Pharmacol Ther</i> . 1997;73(1):67-74.
	Kunze, et al., "Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies"; <i>Drug Metab Dispos</i> . 1996 Apr;24(4):414-21.
	Abstract 4, Johnson, et al., "Structural Characterization of Substrate and Inhibitor Binding to 2C P4505, The Scripps Research Institute, La Jolla, California.
	Abstract 5. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Origin of Substrate Specificity of Cytochromes P450 2C": Chemical and Biochemical Approaches. Daniel Mansuy, Universite Rene Descartes, Paris, France.
	Abstract/Poster 77. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Metabolism Prediction for Cytochrome P450. Isabel Zamora, Lead Molecular Design, XL. Sant Cugat de1 Valles, Spain.
	Abstract/Poster 81. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Sulphenazole Derivatives as Tools for Comparing CYP 2C5 and Human 2C's: Identification of a New High Affinity Substrate (DMZ) Common to Those CYP 2C Enzymes. Patrick m. Dansette, Universite Rene Descartes, Paris, France.
	Marques-Soares, et al., "Sulfaphenazole Derivatives as Tools for Comparing Cytochrome P450 2C5 and Human Cytochromes P450 2Cs: Identification of a New High Affinity Substrate Common to Those Enzymes"; <i>Biochemistry</i> , 2003; 42(21); 6363-6369.
	Wester, et al., "Structure of a Substrate Complex of Mammalian Cytochrome P450 2C5 at 2.3 Å Resolution: Evidence for Multiple Substrate Binding Modes"; <i>Biochemistry</i> ; 2003; 42(21); 6370-6379.
	Zamora, et al., "Predicting Drug Metabolism: A Site of Metabolism Prediction Tool Applied to the Cytochrome P450 2C9"; <i>J. Med. Chem.</i> ; 2003; 46(12); 2313-2324.
	Wester, et al., "Structure of Mammalian Cytochrome P450 2C5 Complexed with Diclofenac at 2.1 Å Resolution: Evidence for an Induced Fit Model of Substrate Binding"; <i>Biochemistry</i> ; 2003; 42(31); 9335-9345
	Tsao, et al., "Identification of Human CYP2C19 Residues that Confer S-Mephenytoin 4'-Hydroxylation Activity to CYP2C9"; <i>Biochemistry</i> ; 2001; 40(7), 1937-1944.
	Longenecker, et al., "Protein crystallization by site-directed mutagenesis of surface residues: Lys to Ala mutations promote crystallization of RhoGDI"; <i>Acta Crystallogr D Bio Crystallogr</i> ; 2001, 57(Pt 5), 679-88.
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)